ALVO Alvotech - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ALVO Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$3.47
Analyst Target
$18.83
+442.7%
Upside
52W High
$11.85
52W Low
$3.45
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ALVO's deterministic health scores signal significant distress: a Piotroski F-Score of 2/9 indicates weak financial health, with poor profitability, negative operating margins, and inconsistent earnings. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given negative operating margins and a low quick ratio of 0.54. Despite a modest 10.6% YoY revenue growth and a 55.59% gross margin, the company exhibits severe earnings volatility, with a -161.1% YoY EPS decline and multiple quarters of massive negative surprises. The stock trades at a 52-week low of $3.45, down 69% over the past year, and analysts' $18.83 target price appears disconnected from current fundamentals. The intrinsic value of $1.61 is well below the current price, suggesting a significant premium is priced in based on speculative growth expectations.
Key Strengths
Strong gross margin of 55.59% indicates efficient production and pricing power
10.6% year-over-year revenue growth suggests top-line expansion in a competitive sector
Positive analyst consensus with a 'buy' recommendation from 6 analysts
Recent quarterly earnings have shown large positive surprises (e.g., +6000%) indicating potential for upside volatility
Low market cap ($1.08B) offers potential for high-growth upside if operational improvements materialize
Key Risks
Piotroski F-Score of 2/9 signals extreme financial weakness, including negative operating margin and inconsistent profitability
Negative operating margin (-2.62%) and lack of consistent earnings undermine sustainable business model
No available Altman Z-Score with negative operating cash flow and low quick ratio (0.54) suggest liquidity and solvency concerns
Massive earnings volatility with multiple quarters of negative EPS surprises exceeding -700%
Stock has declined 69% over the past year and trades at a 52-week low, indicating prolonged market skepticism
AI Fair Value Estimate
Based on comprehensive analysis
$1.61
-53.6% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ALVO against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ALVO from our newsroom.
Newest → oldest
No matching news yet.